HK1064669A1 - Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain. - Google Patents

Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain.

Info

Publication number
HK1064669A1
HK1064669A1 HK04107516A HK04107516A HK1064669A1 HK 1064669 A1 HK1064669 A1 HK 1064669A1 HK 04107516 A HK04107516 A HK 04107516A HK 04107516 A HK04107516 A HK 04107516A HK 1064669 A1 HK1064669 A1 HK 1064669A1
Authority
HK
Hong Kong
Prior art keywords
5üdec
diaza
spiro
medicaments
oxy
Prior art date
Application number
HK04107516A
Other languages
English (en)
Inventor
Helmut Heinrich Buschmann
Werner Gunter Englberger
Tieno Germann
Hagen-Heinrich Hennies
Corinna Maul
Bernd Sundermann
Jorg Holenz
Michael Haurand
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of HK1064669A1 publication Critical patent/HK1064669A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
HK04107516A 2001-06-25 2004-09-30 Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain. HK1064669A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10130020A DE10130020A1 (de) 2001-06-25 2001-06-25 Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
PCT/EP2002/006880 WO2003000699A1 (de) 2001-06-25 2002-06-21 Substituierte 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivate als arzneimittel gegen schmerz

Publications (1)

Publication Number Publication Date
HK1064669A1 true HK1064669A1 (en) 2005-02-04

Family

ID=7689008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107516A HK1064669A1 (en) 2001-06-25 2004-09-30 Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain.

Country Status (30)

Country Link
US (2) US8048890B2 (xx)
EP (1) EP1401841B1 (xx)
JP (1) JP4410554B2 (xx)
KR (1) KR100917112B1 (xx)
CN (1) CN1315840C (xx)
AR (1) AR036098A1 (xx)
AT (1) ATE302782T1 (xx)
AU (1) AU2002310768B2 (xx)
BR (1) BR0211053A (xx)
CA (1) CA2451859C (xx)
CO (1) CO5540301A2 (xx)
CZ (1) CZ20033432A3 (xx)
DE (2) DE10130020A1 (xx)
DK (1) DK1401841T3 (xx)
EC (1) ECSP034924A (xx)
ES (1) ES2245402T3 (xx)
HK (1) HK1064669A1 (xx)
HU (1) HU228774B1 (xx)
IL (2) IL159544A0 (xx)
MX (1) MXPA03012013A (xx)
NO (1) NO332217B1 (xx)
NZ (1) NZ530689A (xx)
PE (1) PE20030146A1 (xx)
PL (1) PL214290B1 (xx)
PT (1) PT1401841E (xx)
RU (1) RU2296128C2 (xx)
SI (1) SI1401841T1 (xx)
SK (1) SK287390B6 (xx)
WO (1) WO2003000699A1 (xx)
ZA (1) ZA200400489B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
PL373956A1 (en) * 2002-08-14 2005-09-19 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
DE102004023635A1 (de) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102005016170A1 (de) * 2005-04-07 2006-10-12 Grünenthal GmbH 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) * 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US9340558B2 (en) 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8580808B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
WO2010051476A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a-binding anti-inflammatory analgesic
US20100279996A1 (en) * 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
WO2010084499A2 (en) * 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US8580809B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
JP6417324B2 (ja) 2012-07-13 2018-11-07 ペイン セラピューティクス インコーポレイテッド τリン酸化を阻害する方法
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
LT3402783T (lt) 2016-01-13 2020-05-11 Grünenthal GmbH 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
SI3402785T1 (sl) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
JP6917379B2 (ja) 2016-01-13 2021-08-11 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
RS60315B1 (sr) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero-)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
AR107434A1 (es) 2016-01-13 2018-05-02 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
NZ758117A (en) 2017-04-12 2022-01-28 Il Dong Pharma Isoxazole derivatives as nuclear receptor agonists and uses thereof
CN109793713B (zh) * 2019-03-26 2021-05-28 李世系 一种用于麻醉的短效催眠镇静的药物组合物及其注射剂制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127065C (xx) * 1964-04-22
GB1227365A (xx) * 1968-07-29 1971-04-07
JPH02164882A (ja) * 1988-12-20 1990-06-25 Yamanouchi Pharmaceut Co Ltd スピロ化合物及びその中間体
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
DE19528472A1 (de) 1995-08-03 1997-02-06 Boehringer Ingelheim Kg Neues Verfahren zur Herstellung von Norbenzomorphan einer Zwischenstufe bei Herstellung von pharmazeutisch wertvollen Benzomorphanderivaten, insbesondere von (-)-(1R,5S,S"R)-3'-Hydroxy-2-(2-methoxypropyl-)-5,9,9-trimethyl-6,7 benzomorphan
EP0854869B1 (en) * 1995-09-29 2004-08-25 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
EP0888344A1 (en) * 1996-03-15 1999-01-07 The Du Pont Merck Pharmaceutical Company Spirocycle integrin inhibitors
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
DE59910360D1 (de) 1998-11-18 2004-09-30 Basf Ag Verfahren zur herstellung von 2-alkyl- 3-(4,5- dihydroisoxazol- 3-yl)-halogenbenzolen
KR20030000243A (ko) 2001-06-22 2003-01-06 이 석 민 동물사료 제조방법 및 그에 적합한 기밀 플라스틱백발효용기
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate

Also Published As

Publication number Publication date
DE50204037D1 (de) 2005-09-29
SI1401841T1 (sl) 2006-02-28
CA2451859C (en) 2011-06-14
IL159544A0 (en) 2004-06-01
AU2002310768B2 (en) 2007-01-11
CO5540301A2 (es) 2005-07-29
RU2296128C2 (ru) 2007-03-27
NO20035730L (no) 2004-02-19
EP1401841B1 (de) 2005-08-24
NO20035730D0 (no) 2003-12-19
HUP0400810A2 (hu) 2004-07-28
KR20040008226A (ko) 2004-01-28
PE20030146A1 (es) 2003-03-15
WO2003000699A8 (de) 2003-11-20
SK287390B6 (sk) 2010-08-09
CN1547584A (zh) 2004-11-17
US20110224172A1 (en) 2011-09-15
MXPA03012013A (es) 2004-03-26
NZ530689A (en) 2005-07-29
CZ20033432A3 (cs) 2004-05-12
US20040192916A1 (en) 2004-09-30
EP1401841A1 (de) 2004-03-31
PL214290B1 (pl) 2013-07-31
HUP0400810A3 (en) 2007-11-28
PT1401841E (pt) 2005-11-30
US8557796B2 (en) 2013-10-15
NO332217B1 (no) 2012-07-30
JP2004536095A (ja) 2004-12-02
IL159544A (en) 2009-05-04
ZA200400489B (en) 2004-10-14
JP4410554B2 (ja) 2010-02-03
KR100917112B1 (ko) 2009-09-11
CN1315840C (zh) 2007-05-16
HU228774B1 (en) 2013-05-28
ECSP034924A (es) 2004-02-26
BR0211053A (pt) 2004-07-20
ATE302782T1 (de) 2005-09-15
WO2003000699A1 (de) 2003-01-03
ES2245402T3 (es) 2006-01-01
SK15702003A3 (sk) 2004-07-07
RU2004100823A (ru) 2005-06-20
PL367748A1 (en) 2005-03-07
DE10130020A1 (de) 2003-12-04
CA2451859A1 (en) 2003-01-03
DK1401841T3 (da) 2005-09-19
US8048890B2 (en) 2011-11-01
AR036098A1 (es) 2004-08-11

Similar Documents

Publication Publication Date Title
HK1064669A1 (en) Substituted 1-oxy-2,8-diaza-spiro Ä4,5Üdec-2-ene derivatives as medicaments for the treatment of pain.
AU2002310768A1 (en) Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
IL160707A0 (en) 1, 8-naphthyridine derivatives as antidiabetics
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
HK1069820A1 (en) Benzoxazinone-derived compounds, their preparation und use as medicaments
IL196301A0 (en) Medicament for the treatment of hapatitis c
MXPA03006250A (es) Compuestos heterociclicos terapeuticos.
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
HK1061026A1 (en) 3,7-Diazabicyclo 3.3.1Ü formulations as antiarhythmic compounds
MXPA03008965A (es) Uso de compuestos de imidazo [1,2-a]-piridinas sustituidas como medicamentos.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
MXPA03006648A (es) Compuestos antitombroticos, su preparacion y su utilizacion como medicamentos.
AP2006003613A0 (en) Oral formulations for 5-HT-receptor agonists, usesand methods of treatment employing the same
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
MXPA03008894A (es) Uso de compuestos de imidazo[1,2-a]-piridin-3-il-amidas e imidazo [1,2-a]-piridin-3-il-aminas sustituidas como medicamentos.
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
MXPA03006162A (es) Derivados de mikanolida, su preparacion y sus usos terapeuticos.
AU2002304883A1 (en) Device for the treatment of tumours